Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Mizuho cuts Boston Scientific stock target to USD 55.00

Analyst downgrade Company update AI-generated analysis

πŸ“‰ Mizuho cut its price target for Boston Scientific from USD 60.00 to USD 55.00 while keeping an Outperform rating.

πŸ’° Second-quarter net sales reached USD 5.44 billion, up 7.5% year over year on a reported basis.

πŸ“ˆ Adjusted earnings per share increased 15% to USD 0.86 in the second quarter of 2026.

πŸ‘” Joseph M. Fitzgerald is named new Chief Operating Officer starting January 1, 2027.

πŸ—οΈ The company will restructure into three segments: Interventional Therapies, Rhythm Solutions, and MedSurg.

⚠️ Analysts cite potential procedure volume pressure from Affordable Care Act and Medicaid changes as a risk.

πŸ“… Third-quarter earnings results are scheduled for release on October 28, 2026.

πŸ’΅ Market capitalization stands at USD 64.4 billion as of October 13, 2026.

πŸ“Š Stock traded at USD 43.31 with a 52-week range between USD 41.39 and USD 105.65.

Bullish Signals
  • Boston Scientific reported strong second-quarter revenue growth of 7.5% year over year, reaching USD 5.44 billion in net sales.
  • Adjusted earnings per share surged 15% to USD 0.86, indicating resilient profitability despite market headwinds.
  • The company is executing a strategic restructuring plan to organize operations into three focused segments: Interventional Therapies, Rhythm Solutions, and MedSurg.
  • Joseph M. Fitzgerald is appointed as the new Chief Operating Officer, signaling continued investment in leadership and operational efficiency.
Risk Factors
  • Mizuho lowered its price target by 8.33% to USD 55.00 due to concerns over near-term procedure volume pressure.
  • Analysts warn that changes involving the Affordable Care Act and Medicaid could negatively impact future procedure volumes in the second half of 2026.
Full Analysis
Mizuho Securities has lowered its price target for Boston Scientific from USD 60.00 to USD 55.00 while maintaining an Outperform rating, citing concerns over near-term procedure volume pressure linked to Affordable Care Act and Medicaid changes ahead of the October 28 earnings report. Despite the analyst downgrade, Boston Scientific reported robust second-quarter financial performance with net sales reaching USD 5.44 billion, representing a 7.5% year-over-year increase. Adjusted earnings per share rose 15% to USD 0.86, demonstrating strong operational execution despite macroeconomic headwinds in the medical device sector. The company is also undergoing strategic restructuring with Joseph M. Fitzgerald set to become Chief Operating Officer on January 1, 2027. This leadership change will reorganize the business into three distinct reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg, aiming to streamline operations and clarify growth drivers. Trading at approximately USD 43.31 as of mid-October 2026, Boston Scientific remains well below its 52-week high but maintains a significant market capitalization of USD 64.4 billion. Investors are closely watching the upcoming third-quarter results to determine if procedure volume pressures will impact the momentum established in the second quarter.